Eyeing Diagnostics Market, Invitrogen Signs Mayo Biomarker Discovery Deal | GenomeWeb

Until this week, Invitrogen’s method for quickly expanding its product pipeline — and its top line — was via acquisition.

Highlighted by its $325 million purchase of Molecular Probes in August 2003, the company has expanded its product offerings like an accordion player stretching his arms, buying and integrating eight companies over the past two years to create a broader multiplatform product portfolio of molecular biology instruments, reagents, and services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.